Clinical Trial Update: Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Zevalin vs observation in older patients with newly diagnosed DLBCL achieving PET-negative complete remission after R-CHOP-like therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma | Phase 3 | Status: TERMINATED | Results posted: 2021-12-16